New labeling for sunitinib malate (Sutent, Pfizer) now includes the first-line treatment of advanced renal cell carcinoma.
This agent was originally approved in January 2006 for the treatment of advanced kidney cancer under an accelerated approval. With the new labeling, the accelerated approval has now been converted to regular approval. cialis canadian pharmacy
Sunitinib is also indicated for patients with gastrointestinal stromal tumors after disease progression with, or intolerance to, imatinib mesylate (Gleevec, Novartis).